Effect of palmitoylethanolamide on degeneration of a human-derived retinal pigment epithelial cell induced by all-trans retinal
Laboratory studyHumansOther animals
- Design
- Laboratory study
- Subjects
- Human-derived ARPE-19 retinal pigment epithelial cells; Abca4-/-Rdh8-/- mice (a model showing features of dry age-related macular degeneration and Stargardt disease)
- Dose used in the study
- Palmitoylethanolamide applied to cells in vitro; injected intraperitoneally in mice (dose not stated)
- Duration
- Not stated in the abstract
- What was measured
- Cell viability and reactive oxygen species after all-trans retinal exposure, JNK/c-Jun/CHOP/Bip apoptosis pathway proteins, and in mice, visual function by electroretinogram, retinal thickness by optical coherence tomography, and light-induced fundus injury.
What the authors reported
Palmitoylethanolamide reduced ARPE-19 cell death and reactive oxygen species (including mitochondrial ROS) triggered by all-trans retinal, improved retinal function, protected retinal pigment epithelial and photoreceptor cells from death, and lessened light-induced fundus damage in the mouse model. It inhibited JNK, phospho-JNK, c-Jun, phospho-c-Jun, Bak, cleaved caspase-3, CHOP and Bip protein levels in both cells and mice.
Limits of this study
A cell-line and mouse-model study; it cannot show effect in people with retinal disease. Funding and conflicts not stated in the abstract.
Source
PubMed 36816211 · doi:10.18240/ijo.2023.02.04
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.